Intermittent hypoxia regulates vasoactive molecules and alters insulin-signaling in vascular endothelial cells

Pragya Sharma1, Yu Dong1,2, Virend K. Somers1, Timothy E. Peterson1,3, Yuebo Zhang1, Shihan Wang1, Guangxi Li4 & Prachi Singh1

Vascular dysfunction and insulin resistance (IR) are associated with obstructive sleep apnea (OSA), which is characterized by frequent episodes of nocturnal intermittent hypoxia (IH). While it is recognized that the balance between vasoconstrictive (endothelin-1) and vasodilatory molecules (nitric oxide, NO) determine vascular profile, molecular mechanisms contributing to vascular dysfunction and IR in OSA are not completely understood. Caveolin-1 is a membrane protein which regulates endothelial nitric oxide synthase (eNOS) activity which is responsible for NO generation and cellular insulin-signaling. Hence, we examined the effects of IH on caveolin-1, eNOS, and endothelin-1 in human coronary artery endothelial cells in the context of IR. Chronic 3-day IH exposure up-regulated caveolin-1 and endothelin-1 expression while reducing NO. Also, IH altered insulin-mediated activation of AKT but not ERK resulting in increased endothelin-1 transcription. Similarly, caveolin-1 overexpression attenuated basal and insulin-stimulated NO synthesis along with impaired insulin-dependent activation of AKT and eNOS, with no effect on insulin-stimulated ERK1/2 phosphorylation and endothelin-1 transcription. Our data suggest that IH contributes to a vasoconstrictive profile and to pathway-selective vascular IR, whereby insulin potentiates ET-1 expression. Moreover, IH may partly mediate its effects on NO and insulin-signaling via upregulating caveolin-1 expression.

Obstructive sleep apnea (OSA) is a common sleep breathing disorder, and is an acknowledged risk factor for cardiovascular disease1. OSA causes transient cessation of breathing during sleep with repetitive episodes of hypoxemia-reoxygenation leading to chronic intermittent hypoxia (IH) exposure1. Endothelial dysfunction is characterized by decreased bioavailability of endothelium-derived nitric oxide (NO), and is highly prevalent in OSA2. Impaired endothelial function is also an important early clinical marker for predicting atherosclerosis and future cardiovascular events. In addition, there is a distinct association of OSA with development of insulin resistance (IR) and hypertension1. Treatment with continuous positive airway pressure therapy improves vascular function, hypertension as well as insulin-sensitivity1,4. This suggests a role of chronic IH in eliciting endothelial dysfunction and IR. However, the molecular mechanisms underlying this association are not completely elucidated.

NO and endothelin-1 (ET-1) are vasoactive compounds expressed in endothelial cells. NO has a vasodilatory effect on blood vessels while ET-1 is a potent vasoconstrictor8. In endothelial cells, NO is generated by endothelial nitric oxide synthase (eNOS) activity, which is regulated by caveolin-1 (cav-1), by directly binding to and blocking the active site of eNOS8. Additionally, cav-1 also regulates insulin signaling7. Considering the dual role of cav-1 in regulating both eNOS and insulin-signaling, we sought to identify and define the role of cav-1 in regulating endothelial NO synthesis and insulin signaling in response to chronic IH using cultured human coronary artery endothelial cells (HCAEC). We tested the hypothesis that IH increases cav-1 and mediates vascular dysfunction and IR with consequent decreases in NO, increases in ET-1, and selectively impaired insulin signaling.

1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 55905, USA. 2Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. 3Department of Neurosurgery Research, Mayo Clinic, Rochester, MN, 55905, USA. 4Department of Pulmonary and Critical Care Medicine, Rochester, MN, 55905, USA. Correspondence and requests for materials should be addressed to P.S. (email: singh.prachi@mayo.edu)
Furthermore, we hypothesized that IH dependent effects on vasoactive compounds and insulin cellular signaling may be mimicked by cav-1 overexpression.

**Results**

**IH decreases NO generation while increasing cav-1 and ET-1 expression.** To understand the role of IH in endothelial cells, we treated HCAEC with IH or normoxia. IH reduces tonic NO generation (p = 0.01, Fig. 1a,b). The IH mediated decreases in NO were similar to that observed by treatment with L-NAME, a known eNOS inhibitor. At the same time, IH does not alter eNOS mRNA (p = 0.28) and protein expression (p = 1.0) but a trend for reduced expression of active phosphorylated eNOS (ser1177) was apparent (p = 0.065, Fig. 1c–e).

Next, we examined the effect of IH on cav-1 expression and show that IH increases cav-1 mRNA (p = 0.04) and protein (p = 0.01, Fig. 1f,g). IH also increases ET-1 mRNA (p = 0.01), intracellular protein expression (p = 0.02) and ET-1 secretion in conditioned media (p = 0.002, Fig. 2).

**IH partially alters insulin cellular signaling pathways.** OSA may potentiate development of insulin-resistance; therefore we examined the effects of chronic IH on insulin cellular actions. Insulin mediated activation of AKT (p = 0.02), eNOS (p = 0.045) and ERK (p = 0.005) cellular signaling pathways was observed in control cells grown in continuous normoxia (Fig. 3). However, insulin was unable to phosphorylate AKT (p = 0.19) in cells exposed to IH (Fig. 3a). Insulin-dependent phosphorylation of eNOS was apparent in cells exposed to IH (p = 0.09, Fig. 3b) especially after 5 and 10 min of insulin treatment. Similar to cells grown in normoxia, insulin-mediated phosphorylation of ERK (p = 0.013) was evident in cells exposed to chronic IH (Fig. 3c). Additionally, insulin stimulated NO generation in cells exposed to normoxia as well as IH. However, even after

---

**Figure 1.** Intermittent hypoxia alters NO generation. Representative images (a) and graph (b) showing decreased NO generation (green fluorescence) in cells exposed to intermittent hypoxia. A23187 was used as a positive control and L-NAME was used as a negative control. Graph and representative Western Blots showing no changes in eNOS mRNA (c), total protein (d), and phosphorylated protein (e). Graph and representative Western Blots showing increases in caveolin-1 mRNA (f) and protein (g). Data are presented as mean ± SEM from at least 3 independent experiments. P values were determined using Wilcoxon Rank Sums test. For pairwise comparison (b), Wilcoxon method was used. *is p < 0.05, † is p < 0.07 compared to normoxia control. N: normoxia (white bars); IH: intermittent hypoxia (black bars); eNOS: endothelial nitric oxide synthase.
Figure 2. Intermittent hypoxia upregulates endothelin-1. Graphs and representative Western blot showing intermittent hypoxia mediated changes in endothelin-1 mRNA (a), intracellular protein (b) and secreted protein (c). Data are presented as mean ± SEM from at least 3 independent experiments. P values were determined using Wilcoxon Rank Sums test. *is p < 0.05 compared to normoxia control. N: normoxia (white bars); IH: Intermittent hypoxia (black bars); ET-1: endothelin-1.

Figure 3. Intermittent hypoxia alters insulin dependent cellular signaling pathways. Representative Western blots and graphs showing intermittent hypoxia induced changes in insulin mediated phosphorylation of AKT (a), eNOS (b) and ERK (c). Data are presented as mean ± SEM from at least 3 independent experiments. Overall P values were determined using Wilcoxon Rank Sums test. For pairwise comparison, Wilcoxon method was used. *is p < 0.05 as compared to 0 time point for Normoxia (N) or intermittent hypoxia (IH) group respectively. White bars depict data from N group, black bars depict data from IH group.
insulin stimulation, NO levels remained lower in cells exposed to IH (p < 0.001, Fig. 4a,b). Importantly, insulin stimulated ET-1 transcription was enhanced in cells exposed to IH (p = 0.006, Fig. 4c).

Differential effects of cav-1 overexpression on cellular insulin actions. Cav-1 regulates insulin-signaling7 and IH upregulates cav-1 expression; therefore we investigated the effects of increased cav-1 on insulin-dependent activation of signaling pathways including AKT and ERK1/2, and downstream activation of eNOS in HCAEC. Cav-1 overexpression impaired insulin-dependent activation of AKT (p = 0.02, Fig. 5a) and eNOS (p = 0.03, Fig. 5b). Of note, 30 min of insulin exposure was able to increase AKT phosphorylation in control adnull cells. Also, attenuation of insulin-dependent signaling by increased cav-1 is selective since insulin-stimulated phosphorylation of ERK1/2 (p = 0.02, Fig. 5c) was not affected in cells treated with adcav-1. Furthermore, cav-1 overexpression attenuated basal and insulin-stimulated NO synthesis (p < 0.0001, Fig. 6a,b). Insulin dependent upregulation of ET-1 mRNA transcription is not altered by increases in cav-1 expression (p < 0.001, Fig. 6c).

Discussion
In this study we demonstrate for the first time that IH alters insulin-signaling and stimulates cav-1 expression which may together promote changes in HCAEC consistent with vasoconstriction. These findings have important implications for understanding mechanisms contributing to the increased risk of diabetes and hypertension in patients with OSA.

Endothelial dysfunction, high blood pressure, and IR in OSA likely contribute to the increased cardiovascular risk in OSA patients1. It has been reported that reduced plasma levels of vasodilator NO correlate with the severity of IH2, while plasma levels of vasoconstrictor ET-1 are elevated in OSA10. These observations suggest involvement of IH in regulation of vascular function in OSA, but the underlying molecular mechanisms are not known. Our study is the first to examine the role of IH in mediating changes in cav-1, NO, ET-1, and insulin-signaling in human coronary artery endothelial cells.
Cav-1 has an important role in regulating NO-dependent vasodilation in endothelial cells. eNOS, as a source of bioavailable NO in the vascular endothelium, plays a critical role in maintaining vascular homeostasis by exerting vasodilatory, anti-inflammatory and anti-thrombotic effects while actively promoting endothelial repair, regeneration and vascularization\(^1\). Over-expression of cav-1 inhibits eNOS activity, endothelial barrier function, and angiogenic responses to exogenous VEGF and tissue ischemia\(^2\). On the other hand, in cav-1 (−/−) knock-out mice, constitutive activation of eNOS is reported to cause microvascular hyperpermeability, which is reversed by L-NAME (specific NOS inhibitor) injection\(^3\). This suggests that cav-1 could potentially have a role in modulating endothelial function in OSA via IH. In our in-vitro model of OSA we demonstrate that cav-1 expression increased after IH exposure along with a decline in NO. Moreover, IH had a stimulatory effect on the expression as well as secretion of ET-1, which is known to have vasoconstrictive properties\(^5\). IH mediated increases in ET-1 are consistent with observations from several animal models of OSA\(^13\). Furthermore, both cav-1 and ET-1 have been shown to be modulated by transcription factor Hif-1\(^14\),\(^16\), which is known to play an important role in IH as well\(^17\). Therefore, it is likely that Hif-1 represents a common underlying mechanism responsible for altering both cav-1 and ET-1 in IH and may be targeted to attenuate detrimental effects of IH on vascular function.

In addition to the role of cav-1 in regulating eNOS activity, cav-1 is also known to alter insulin signaling\(^18\). Cav-1 is essential to stabilize the insulin receptor and is known to differentially modulate insulin-dependent cellular signaling pathways\(^7\),\(^18\). Furthermore, cav-1 has been shown to be important for insulin uptake in vascular endothelial cells\(^19\). Therefore, it is likely that IH mediates its effects on insulin signaling in part via

---

**Figure 5.** Caveolin-1 (cav-1) expression alters insulin cellular signaling. Cav-1 overexpressing (adcav-1, black bars) or control (adnull, light gray bars) cells were treated with insulin (100 nM) for increasing time periods. Representative western blot and densitometry graph showing that cav-1 overexpression causes attenuation of insulin dependent phosphorylation of AKT (a) and eNOS (b). Insulin-mediated ERK phosphorylation is not altered by caveolin-1 expression (c). Data are mean ± SEM. Overall P values were determined using Wilcoxon Rank Sums test. For pairwise comparison, Wilcoxon method was used. *p ≤ 0.05 compared to 0 time point adnull or adcav-1 treated cells respectively. #p < 0.05 compared to ad-null treated cells at the same time point.
increasing cav-1 expression. In addition to regulating metabolism, insulin is also critical for regulation of endothelial vasomotor function by increasing vascular endothelial NO production. At the cellular level, this regulation of endothelium-mediated vasoactivity is actually a balance between phosphatidylinositol 3-kinase (PI3K)-dependent insulin-signaling pathways known to regulate endothelial NO production and mitogen activated protein kinase (MAPK)-dependent insulin-signaling pathways that regulate the secretion of the vasoconstrictor ET-1. The normally functioning endothelium keeps ET-1 and NO in balance. Based on work by us and others, this balance between vasodilator and vasoconstrictor responses to insulin is altered with age and with IR. We have previously shown that insulin promotes vasodilation in healthy young adults but causes vasoconstriction in healthy elderly individuals, suggesting an attenuation of the vasodilator effect and/or a potentiation of the vasoconstriction action of insulin in the elderly. It was speculated that the vasoconstrictor response to insulin might further potentiate IR in the elderly. Similar to aging, with IR, the PI3K-NO pathway is reduced while the MAPK-ET1 pathway is unaffected or stimulated, leading to endothelial dysfunction in animal models or humans. We show that increased cav-1 expression alters the balance between insulin-mediated PI3K-NO and MAPK-ET1 signaling such that insulin contributes to a more vasoconstrictive profile. Furthermore, while cav-1 binds to and directly regulates eNOS activity via interference with Ca2+ -dependent NO synthesis, insulin activates eNOS in a Ca2+ -independent manner via AKT. There is evidence that activation of AKT may exert anti-atherogenic effects through posttranscriptional activation of eNOS by phosphorylation at the ser1177 amino acid residue. Whether cav-1 has a role in regulation of insulin-mediated increases in NO generation is not known. We demonstrate that increased cav-1 expression attenuates insulin-dependent NO synthesis in endothelial cells (Fig. 6). Our results indicate that cav-1 selectively impairs insulin-dependent signaling with preferential inhibition of AKT versus ERK1/2 signaling. Vasoconstrictor and mitogenic effects of ET-1 may be implicated in

![Figure 6](image-url)

**Figure 6.** Caveolin-1 overexpression attenuates insulin mediated cellular actions. Representative images (a) and graph (b) showing NO generation (green fluorescence) in basal and insulin stimulated conditions in control (adnull) and caveolin-1 overexpressing (adcav-1) cells. Graph (c) showing stimulation of ET-1 mRNA expression by insulin (100 nM) in control (ad-null) and cav-1 overexpressing cells. Data are mean ± SEM. Overall P values were determined using Wilcoxon Rank Sums test. For pairwise comparison, Wilcoxon method was used. *p < 0.05 compared to adnull cells w/o insulin, #p < 0.05 compared to adcav-1 cells w/o insulin and ^p < 0.05 compared to adnull cells with insulin.
increased cardiovascular risk in patients with OSA. The findings related to partial impairment of insulin cellular signaling pathways are consistent with previous reports in different cell types. Interestingly, in contrast to caveolin-1 overexpressing cells which impaired insulin dependent activation of AKT and eNOS, chronic exposure to IH only altered insulin-mediated phosphorylation of AKT while insulin mediated activation of eNOS and NO generation was intact. Furthermore, IH exposure enhanced insulin-mediated ET-1 transcription. Intriguingly, insulin has been shown to activate eNOS via AMPK pathway in human platelets. These findings warrant further in-depth investigation of cellular signaling pathways being altered with IH. Nevertheless, our study provides a novel molecular mechanism for the insulin-mediated changes in vascular tone and development of selective insulin-resistance with IH exposure.

The strength of our study is in the in-vitro IH model which has been previously shown to mimic molecular changes seen in OSA subjects and use of human coronary artery endothelial cells which are relevant to development of atherosclerosis. Furthermore, we have used both eNOS phosphorylation and DAFA/DAF-43 based NO detection to inform on eNOS activity in the presence of appropriate positive and negative controls. Our study has several limitations including those related to in-vitro study design, which merits further investigation in OSA patients. To conclusively prove the role of caveolin-1 in IH-mediated changes in eNOS and insulin signaling, caveolin-1 silencing experiments may be envisaged. However, previous studies have shown that the lack of caveolin-1 can itself increase basal eNOS activity and impair insulin-signaling as well. Therefore, considering the requirement for optimal caveolin-1 levels to regulate eNOS and facilitate insulin signaling, it is not feasible to undertake caveolin-1 silencing experiments in conditions of IH and we restricted our studies only to examining the contribution of increased caveolin-1 on basal and insulin-stimulated eNOS activity in normoxic conditions.

In conclusion, we show that IH promotes imbalance between vasodilatory and vasoconstrictive molecules in vascular endothelial cells. The effects of IH are further potentiated by enhanced insulin-stimulated ET-1 transcription in cells treated with IH. Furthermore, IH induces caveolin-1 expression. Increased caveolin-1 expression may in-turn selectively alter insulin-signaling so as to promote vasoconstrictive responses by attenuating NO generation via the AKT pathway but not altering dependent stimulation of ET-1 transcription via the ERK1/2 pathway. Our findings identify a potential caveolin-1 dependent mechanism through which OSA may contribute to insulin-resistance as well as a vasoconstrictive profile. It would be of clinical interest to determine whether increases in caveolin-1 are also evident in OSA patients and can be attenuated by continuous positive airway pressure treatment. Furthermore, it would be important to determine if increases in caveolin-1 are also evident in other tissues such as liver, pancreas and heart. Nevertheless, our studies provide a molecular basis for potentially targeting vascular caveolin-1 to improve insulin-signaling and vascular profile in OSA.

Materials and Methods

Cell Culture and Treatments. Human coronary artery endothelial cells (HCAEC) and cell culture reagents were obtained from Lonza, Clonetech (Mountain View, CA). Cells were grown in endothelial growth media 2 (EGM-2) supplemented with growth factors and 5% FBS. All the experiments were performed at 3–5 passages with 70–80% confluence. Intermittent hypoxia was achieved by cycles of 30 min 0.1% O2 + 5% CO2 and 30 min 21% O2 + 5% CO2 repeated 9 times each day using Oxycycler (Biospherix, Lacona, NY) through regulated expulsion of oxygen and nitrogen. Cells grown in continuous 21% O2 + 5% CO2 were used as normoxic controls for these experiments. This in-vitro model of IH has been previously demonstrated to mimic molecular changes observed in OSA patients. Cells were treated with IH for 3 days for protein and 1 day for RNA analyses. The length of IH exposure is based on experiments examining changes in caveolin-1 over period of 1 to 5 days (data not shown). IH exposed cells were either used for NO staining and insulin-signaling experiments or frozen immediately for protein or mRNA analysis. To achieve maximal activation of insulin signaling pathways, 100 nM insulin concentration was used. Visual assessment of cells was undertaken at each step to ensure viability of the cells and optimal data quality.

Caveolin-1 Overexpression. To assess the effect of caveolin-1 overexpression in HCAEC, cells were infected with adenovirus expression vector encoding caveolin-1 (adca1; Vector Biolabs, Malvern, PA). Cells infected with null adenovirus (adnuv) were used as a control. Cells were serum-starved overnight and were infected with adenovirus (MOI 40) for 24 hrs. Infected cells were allowed to grow for another 24 hrs. in complete growth medium. To ascertain whether caveolin-1 overexpression has an effect on insulin-dependent signaling, adca1 cells were serum-starved overnight and treated with 100 nM Insulin for different time points (0–30 min, 6 hrs).

Protein Analyses. Intracellular protein expression in treated cells was determined by Western blot analysis. Primary antibodies used include eNOS (#5880 S, 1:1000, Cell Signaling, Danvers, MA), p-eNOS (#9570, Ser 1177, 1:1000, Cell Signaling), caveolin-1 (#610407, 1:2000, BD transduction Laboratories, San Diego, CA), pAKT (#9275, 1:1000, Cell Signaling, AKT (#9272, Ser 473, 1:1000, Cell Signaling), and GAPDH(#2118, 1:2500, Cell Signaling). Complete Western blots for the representative images are presented in supplementary material. The optical density of the band was measured using ImageJ software (NIH). The protein expression levels were normalized to GAPDH or total protein (for experiments measuring phosphorylated protein) and represented as percent increase as compared to relative controls. Secreted ET-1 levels were assessed in the condition medium using quanthink ELISA kit (R&D, Minneapolis, MN) as per manufacturers’ instruction. For ELISA, all the samples and standards were run in duplicates. The results were expressed as percentages relative to the respective controls.

mRNA Analysis. Total RNA was isolated from treated cells by Purelink RNA mini kit and reverse transcribed to cDNA using high-capacity cDNA transcription kit. Commercially available validated TaqMan gene-specific
expression assays were used to quantify the transcripts for cave-1, eNOS, ET-1 and GAPDH (endogenous control) in the cDNA library. RTPCR was performed on iCycler IQ real time PCR detection system (Biorad, Hercules, CA). RT-PCR reactions were performed according to manufacturer’s instructions. All samples and standards were run in triplicate and GAPDH was used as internal control. Relative standard curves from known dilutions of cDNA from HCAEC were used to semi-quantify the gene expression. The gene expression was expressed as normalized ratio and percent change compared to relative control group.

**Nitric oxide Detection.** To determine the effects of IH and cave-1 overexpression on basal and insulin-stimulated NO production, cells grown in IH or normoxia were treated with insulin (100 nM), L-NAME (negative control, 5 mM), and A23187 (positive control, 5 µM) in HBSS buffer containing L-arginine (100 µM) for 1 hour. Subsequent to this treatment, cells were washed with HBSS and incubated with cell permeable fluorescent NO indicator 4- amino- 5- methylamino-2′-1 hour. Subsequent to this treatment, cells were washed with HBSS and incubated with cell permeable fluorescent NO indicator 4- amino- 5- methylamino-2′-difluorescein diacetate (DAF-FM-Da, Life Technologies, Grand Island, NY) (1 µM, 30 min) in HBSS buffer containing L-arginine for 30 min. Prior treatment with insulin or other controls were repeated for 30 min and production of NO was visualized by emission of green light (515 nm) upon excitation at 489 nm using fluorescence imaging system (X-cite 120). Images were captured using a Nikon digital camera attached to an inverted light microscope at 40X magnification. Fluorescence intensity was quantified using ImageJ (NIH) software for at least 25 cells per treatment during each experiment. Corrected total cell fluorescence was calculated by subtracting the integrated fluorescence density value obtained for the cell with the multiple of area of the selected cell and mean fluorescence of background readings. These corrected total cell fluorescence values were used for further analysis. Each experiment was independently repeated at least three times.

**Statistical Analysis.** Data are presented as Mean ± SEM. The differences between the groups were assessed using nonparametric Wilcoxon Rank Sums test. For experiments with more than two groups, Wilcoxon method was used for paired comparisons. JMP software from SAS Institute Inc version 10.0 was used for all analysis and P < 0.05 was considered statistically significant. All western blots and in vitro experiments were repeated independently on at least three occasions.

**Data Availability Statement**

The data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**References**

1. Somers, V. K. et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. *J Am Coll Cardiol* 52, 686–717, https://doi.org/10.1016/j.jacc.2008.05.002 (2008).

2. Atkeson, A. & Jelic, S. Mechanisms of endothelial dysfunction in obstructive sleep apnea. *Vasc Health Risk Manag* 4, 1327–1335 (2008).

3. Schubert, W. et al. Microvascular hyperpermeability in caveolin-1 (−/−) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. *The Journal of biological chemistry* 277, 40091–40098, https://doi.org/10.1074/jbc.M205948200 (2002).

4. Ip, M. S. et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. *Am J Respir Crit Care Med* 162, 2166–2171, https://doi.org/10.1164/ajrccm.162.6.2002126 (2000).

5. Yanagisawa, M. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 332, 411–415, https://doi.org/10.1038/332411a0 (1988).

6. Ju, H., Zou, R., Venema, V. J. & Venema, R. C. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits nitric oxide synthase activity. *The American journal of physiology* 272, 18522–1852 (1997).

7. Nystrom, E. H., Chen, H., Cong, L. N., Li, Y. & Quon, M. J. Caveolin-1 interacts with the insulin receptor and can differentially modulate insulin signaling in transfected Cos-7 cells and rat adipose cells. *Mol Endocrinol* 13, 2013–2024, https://doi.org/10.1210/mend.13.12.0392 (1999).

8. Singh, P. & Somers, V. K. Obstructive sleep apnea, diabetes, and obesity: partners in crime? *Sleep Medicine*, https://doi.org/10.1016/j.sleep.2016.06.009 (2016).

9. Weiss, J. W., Liu, Y., Li, X. & Ji, E. S. Nitric oxide and obstructive sleep apnea. *Respir Physiol Neurobiol* 184, 192–196, https://doi.org/10.1016/j.resp.2012.08.011 (2012).

10. Phillips, B. G. et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. *J Hypertens* 17, 61–66 (1999).

11. Behrendt, D. & Ganz, P. Endothelial function. From vascular biology to clinical application. *The American journal of cardiology* 90, 401–408 (2002).

12. Bauer, P. M. et al. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. *Proceedings of the National Academy of Sciences of the United States of America* 102, 204–209, https://doi.org/10.1073/pnas.040692102 (2005).

13. Kanagy, N. L., Walker, B. R. & Nelin, L. D. Role of endothelin in intermittent hypoxia-induced hypertension. *Hypertension* 37, 511–515 (2001).

14. Gras, E. et al. Endothelin-1 mediates intermittent hypoxia-induced inflammatory vascular remodeling through HIF-1 activation. *J Appl Physiol (1985)* 120, 437–443, https://doi.org/10.1152/japplphysiol.00641.2015 (2016).

15. Foster, G. E., Poulou, M. J. & Hanly, P. J. Intermittent hypoxia and vascular function: implications for obstructive sleep apnoea. *Exp Physiol* 92, 51–65, https://doi.org/10.1113/expphysiol.2006.035204 (2007).

16. Wang, Y. et al. Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. *Proceedings of the National Academy of Sciences of the United States of America* 109, 4892–4897, https://doi.org/10.1073/pnas.112129109 (2012).

17. Toffoli, S. et al. Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1. *Angiogenesis* 12, 47–67, https://doi.org/10.1007/s10456-009-9131-y (2009).

18. Cohen, A. W., Combs, T. P., Scherer, P. E. & Lisanti, M. P. Role of caveolin and caveolae in insulin signaling and diabetes. *American journal of physiology* 285, E1151–1160 (2003).

19. Wang, H., Wang, A. X. & Barrett, E. J. Caveolin-1 is required for vascular endothelial insulin uptake. *American journal of physiology* 300, E134–144, https://doi.org/10.1152/ajpendo.00498.2010 (2011).

20. Muniyappa, R. & Sowers, J. R. Role of insulin resistance in endothelial dysfunction. *Rev Endocr Metab Disord* 14, 5–12, https://doi.org/10.1007/s11154-012-9229-1 (2013).
21. Hausberg, M. et al. Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. *Hypertension* **29**, 700–705 (1997).

22. Meneilly, G. S., Elliot, T., Bryer-Ash, M. & Floras, J. S. Insulin-mediated increase in blood flow is impaired in the elderly. *J Clin Endocrinol Metab* **80**, 1899–1903, [https://doi.org/10.1210/jcem.80.6.777638](https://doi.org/10.1210/jcem.80.6.777638) (1995).

23. Montagnani, M., Chen, H., Barr, V. A. & Quon, M. J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). *The Journal of biological chemistry* **276**, 30392–30398, [https://doi.org/10.1074/jbc.M103702200](https://doi.org/10.1074/jbc.M103702200) (2001).

24. Park, K. et al. Serine phosphorylation sites on IRS2 activated by angiotensin II and protein kinase C to induce selective insulin resistance in endothelial cells. *Molecular and cellular biology* **33**, 3227–3241, [https://doi.org/10.1128/MCB.00506-13](https://doi.org/10.1128/MCB.00506-13) (2013).

25. Montagnani, M., Chen, H., Barr, V. A. & Quon, M. J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). *The Journal of biological chemistry* **276**, 30392–30398, [https://doi.org/10.1074/jbc.M103702200](https://doi.org/10.1074/jbc.M103702200) (2001).

26. De Nigris, V. et al. Short-term high glucose exposure impairs insulin signaling in endothelial cells. *Cardiovasc Diabetol* **14**, 114, [https://doi.org/10.1186/s12933-015-0278-0](https://doi.org/10.1186/s12933-015-0278-0) (2015).

27. Fleming, I. et al. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. *Thromb Haemost* **90**, 863–871, [https://doi.org/10.1160/TH03-04-0228](https://doi.org/10.1160/TH03-04-0228) (2003).

28. Hoffmann, M. S., Singh, P., Wolk, R., Narkiewicz, K. & Somers, V. K. Obstructive sleep apnea and intermittent hypoxia increase expression of dual specificity phosphatase 1. *Atherosclerosis* **231**, 378–383, [https://doi.org/10.1016/j.atherosclerosis.2013.09.033](https://doi.org/10.1016/j.atherosclerosis.2013.09.033) (2013).

29. Cohen, A. W. et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. *Am J Physiol Cell Physiol* **285**, C222–C235, [https://doi.org/10.1152/ajpcell.00060.2003](https://doi.org/10.1152/ajpcell.00060.2003) (2003).

30. Singh, P., Peterson, T. E., Sert-Kuniyoshi, F. H., Jensen, M. D. & Somers, V. K. Leptin upregulates caveolin-1 expression: implications for development of atherosclerosis. *Atherosclerosis* **217**, 499–502, [https://doi.org/10.1016/j.atherosclerosis.2010.10.012](https://doi.org/10.1016/j.atherosclerosis.2010.10.012) (2011).

31. Lynn, M. A. et al. Fatty acids differentially modulate insulin-stimulated endothelial nitric oxide production by an Akt-independent pathway. *J Investig Med* **52**, 129–136, [https://doi.org/10.1136/jim-52-02-22](https://doi.org/10.1136/jim-52-02-22) (2004).

Acknowledgements

The study was supported by NIH R01 grant HL65176 to VKS and PS; and American Heart Association grant 17GRNT33660138 to PS.

Author Contributions

Conceptualization, V.K.S., T.E.P., P.S. Methodology: P.S., T.E.P., P.S., Y.D. data generation and analysis: P.S., Y.D., Y.Z. and P.S. Writing – original draft, P.S., Y.D., Y.Z., P.S. Writing-Review and editing, P.S., V.K.S., T.E.P., Y.Z., Y.D., S.W., G.L., P.S. Funding acquisition, V.K.S., T.E.P., P.S.

Additional Information

Supplementary information accompanies this paper at [https://doi.org/10.1038/s41598-018-32490-3](https://doi.org/10.1038/s41598-018-32490-3).

Competing Interests: Dr. V.K.S. has received grant support from Philips Respironics Foundation (gift to Mayo Foundation) and has served as a consultant for Respicardia, ResMed, Sorin Inc., U-Health, GlaxoSmithKline, Rhonda Grey, Dane Garvin, Philips Respironics, Biosense Webster. He is also working with Mayo Health Solutions and their industry partners on intellectual property related to sleep and cardiovascular disease. All other authors declare no potential conflict of interest.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2018